Dr. Marc Pretze
Marc Pretze studied chemistry at the Technical University of Dresden. He wrote his dissertation at the Research Center Dresden-Rossendorf, where he worked on the development of marker building blocks for the introduction of fluorine-18 into bioactive compounds, using Staudinger ligation. During his PhD at the Helmholtz-Zentrum Dresden-Rossendorf, he developed potential Fluor-18 labeled radiotracers based on peptides and low molecular weight compounds for the characterization of Eph receptor expressing tumor cells. He has been working as a post-doc on the establishment of Gallium-68, Fluor-18 and Copper-64 labeled radiotracers for tumor research and routine clinical use since 2013 and on gold nanoparticles as a multimodal platform for the diagnosis and therapy of tumors since 2014. For the past two years, he has also been responsible for the GMP-compliant production of radiopharmaceuticals at the Institute of Clinical Radiology and Nuclear Medicine.